Talphera Reports 50% Enrollment in CRRT Study Amid FDA Collaboration

Talphera Advances CRRT Study Amid Regulatory Collaboration

Talphera, Inc., a specialized pharmaceutical company focused on developing innovative therapies for medical settings, announces a major milestone in its NEPHRO-CRRT registrational study, achieving 50% patient enrollment with 35 out of 70 participants. This advancement follows strategic modifications made in partnership with the FDA, which resulted in nearly a 60% decrease in the total patient enrollment target and a revision of enrollment criteria. The company's new approach emphasizes collaboration with medical ICUs and nephrologists as principal investigators, leading to a remarkable 90% enrollment success rate from these targeted clinical sites.

CEO Vince Angotti expresses optimism about the progress, highlighting plans to file a Premarket Approval (PMA) for an unprecedented regional anticoagulant specifically designed for Continuous Renal Replacement Therapy (CRRT). The modifications and focus on nephrologists, who provide critical insights into patient care and therapy needs, have positioned Talphera to address an urgent gap in the market for effective CRRT anticoagulants. Angotti notes that feedback from physicians underscores the critical need for enhanced anticoagulant options to improve patient outcomes in acute kidney injury treatment settings.

In addition to its clinical initiatives, Talphera is gearing up for a virtual investor and analyst event scheduled for March 23, 2026. This event will feature distinguished nephrologists Dr. Blaithin McMahon and Dr. Joao Teixeira, who will provide expert perspectives on CRRT practices and the implications of the ongoing study. The webinar will allow participants to engage directly during a Q&A session, with a comprehensive slide presentation becoming available for replay for 90 days. This outreach demonstrates Talphera's commitment to transparency and collaboration within the medical community, ensuring that stakeholders stay informed on the advances of their investigational therapies.

As Talphera continues to progress towards its clinical objectives, these developments signal a promising trajectory for the company and its innovative solutions in nephrology.